Patents by Inventor Francois Dautry

Francois Dautry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SiRNA-based cancer treatment
    Patent number: 8318689
    Abstract: A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3? or 5? ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: November 27, 2012
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Annick Harel-Bellan, Slimane Ait-Si-Ali, Florence Cabon-Georget, Anne Chauchereau, Francois Dautry
  • Inhibitor oligonucleotides and their use for specific repression of a gene
    Publication number: 20080287385
    Abstract: A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3? or 5? ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.
    Type: Application
    Filed: February 28, 2008
    Publication date: November 20, 2008
    Applicant: Centre National de la Recherche Scientifique - CNRS, a corporation of France
    Inventors: Annick Harel-Bellan, Slimane Ait-Si-Ali, Florence Cabon-Georget, Anne Chauchereau, Francois Dautry, Luis Martinez
  • Inhibitor oligonucleotides and their use for specific repression of a gene
    Patent number: 7371735
    Abstract: A method of treating a disease resulting from the expression of a harmful gene is described. The method includes the step of administering a therapeutically effective amount of a pharmaceutical composition having at least one double stranded oligonucleotide including two complementary oligonucleotide sequences forming a hybrid. Each oligonucleotide sequence comprises at one of their 3? or 5? ends one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid. One of the oligonucleotide sequences is substantially complementary to a target sequence belonging to a DNA or messenger RNA molecule of a gene coding a mutated or nonmutated androgen receptor.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: May 13, 2008
    Assignee: Centre National de la Recherche Scientifique-CNRS
    Inventors: Annick Harel-Bellan, Slimane Ait-Si-Ali, Florence Cabon-Georget, Anne Chauchereau, Francois Dautry
  • Inhibitor oligonucleotides and their use for specific repression of a gene
    Publication number: 20050215497
    Abstract: The invention concerns a double-stranded oligonucleotide characterized in that it consists of two complementary oligonucleotide sequences forming a hybrid comprising each at one of their 3? or 5? ends one to five non-matched nucleotides forming single-stranded ends overlapping from the hybrid, one of said oligonucleotide sequences being substantially complementary of a target sequence belonging to a DNA or RNA molecule to be specifically repressed. The invention also concerns the use of said oligonucleotides in pharmaceutical compositions for treating cancers.
    Type: Application
    Filed: November 8, 2002
    Publication date: September 29, 2005
    Inventors: Annick Harel-Bellan, Slimane Ait-Si-Ali, Florence Cabon-Georget, Anne Chauchereau, Francois Dautry, Luis Martinez